Skandinaviska Enskilda Banken (SEB)
FATE icon

Skandinaviska Enskilda Banken (SEB)’s Fate Therapeutics FATE Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-309,359
Closed -$3.12M – 906
2022
Q4 		$3.12M Sell
309,359
-1,972
-0.6% -$37K 0.02% 447
2022
Q3 		$6.98M Buy
311,331
+117,694
+61% +$3.4M 0.05% 297
2022
Q2 		$4.8M Buy
193,637
+13,017
+7% +$359K 0.04% 371
2022
Q1 		$7M Buy
180,620
+6,916
+4% +$268K 0.04% 333
2021
Q4 		$10.4M Buy
173,704
+31,753
+22% +$1.8M 0.05% 281
2021
Q3 		$8.41M Hold
141,951
– – 0.05% 319
2021
Q2 		$12.3M Buy
141,951
+119,351
+528% +$9.62M 0.08% 250
2021
Q1 		$1.86M Hold
22,600
– – 0.01% 686
2020
Q4 		$2.06M Buy
22,600
+15,000
+197% +$931K 0.01% 642
2020
Q3 		$304K Sell
7,600
-16,300
-68% -$569K ﹤0.01% 875
2020
Q2 		$820K Buy
+23,900
New +$712K 0.01% 754

Other funds holding FATE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s FATE Position: Q1 2023 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 309,359 shares — an estimated $3.12M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in FATE in Q2 2020 and held it in 11 quarters. The position peaked at $12.3M in Q2 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 309,359 Fate Therapeutics shares in Q1 2023, an estimated $3.12M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Fate Therapeutics in Q2 2020 and held it in 11 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Fate Therapeutics position peaked at $12.3M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2023, filed 11 May 2023.